- Home
- YMM vs BLCO Comparison
YMM vs BLCO Comparison
Compare YMM & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMM | BLCO |
|---|---|---|
| Founded | 2011 | 1853 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 7.1B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | YMM | BLCO |
|---|---|---|
| Price | $8.75 | $20.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 15 |
| Target Price | $12.55 | ★ $21.64 |
| AVG Volume (30 Days) | ★ 6.4M | 927.2K |
| Earning Date | 11-19-2026 | 10-28-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $0.38 | $7.83 |
| Revenue Next Year | $7.65 | $5.90 |
| P/E Ratio | $18.30 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $7.46 | $14.44 |
| 52 Week High | $13.09 | $21.36 |
Technical Indicators
Market Signals| Indicator | YMM | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 74.17 |
| Support Level | $8.20 | $15.30 |
| Resistance Level | $8.96 | N/A |
| Average True Range (ATR) | 0.28 | 0.68 |
| MACD | -0.01 | 0.40 |
| Stochastic Oscillator | 83.25 | 77.92 |
Price Performance
Historical ComparisonAbout YMM Full Truck Alliance Co. Ltd. (each representing 20)
Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.